A treatment as prevention trial to eliminate hepatitis C among men who have sex with men living with HIV in the Swiss HIV Cohort Study.

Braun, Dominique L; Hampel, Benjamin; Ledergerber, Bruno; Grube, Christina; Nguyen, Huyen; Künzler-Heule, Patrizia; Shah, Cyril; Salazar Vizcaya, Luisa; Conen, Anna; Flepp, Markus; Stöckle, Marcel; Béguelin, Charles; Schmid, Patrick; Rougemont, Mathieu; Delaloye, Julie; Bernasconi, Enos; Nicca, Dunja; Böni, Jürg; Rauch, Andri; Kouyos, Roger D; ... (2021). A treatment as prevention trial to eliminate hepatitis C among men who have sex with men living with HIV in the Swiss HIV Cohort Study. Clinical infectious diseases, 73(7), e2194-e2202. The University of Chicago Press 10.1093/cid/ciaa1124

Preview

Text Unbenannt.pdf - Accepted Version Available under License Publisher holds Copyright. Download (805kB) | Preview

BACKGROUND

In 2016, the World Health Organization (WHO) introduced global targets for the elimination of hepatitis C (HCV) by 2030. We conducted a nationwide HCV micro-elimination program among men who have sex with men (MSM) living with HIV from the Swiss HIV Cohort Study (SHCS) to test whether the WHO goals are achievable in this population.

METHODS

During phase A (10/2015-06/2016), we performed a population-based and systematic screening for HCV-RNA among MSM from the SHCS. During phase B (06/2016-02/2017) we offered treatment with HCV direct-acting agents (DAAs) to MSM identified with a replicating HCV infection. During phase C (03/2017-11/2017), we offered re-screen to all MSM for HCV-RNA and initiated DAA treatment in MSM with replicating infections (Clinicaltrials.gov NCT02785666).

FINDINGS

We screened 3'715/4'640 (80%) MSM and identified 177 with replicating HCV infections (4.8%); 150 (85%) of which started DAA treatment and 149 (99.3%) were cured. We re-screened 2'930/3'538 (83%) MSM with a prior negative HCV-RNA and identified 13 (0.4%) with a new HCV infection. At the end of the micro-elimination program, 176/190 MSM (93%) were cured, and the HCV incidence rate declined from 0.53 per 100 patient-years (95% confidence interval [CI] 0.35, 0.83) prior to the intervention to 0.12 (CI 0.03, 0.49) by the end of 2019.

INTERPRETATION

A systematic and population-based HCV micro-elimination program among MSM living with HIV was feasible and resulted in a strong decline in HCV incidence and prevalence. Our study can serve as a model for other countries aiming to achieve the WHO HCV elimination targets.

Interest & Impact

Downloads

188 since deposited on 17 Aug 2020
33 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item